Background: Improved methods for the early and specific detection of ovarian cancer are needed.
Background
Ovarian cancer is the sixth most commonly diagnosed cancer in the world, accounting 4 % of all cancers in women [1] , and it is the leading cause of death from gynecologic malignancies in the western world [2, 3] . Most ovarian cancers are first diagnosed in an advanced stage because patients' symptoms may be minimal or nonspecific and no reliable biomarkers are available [4] . Tumor-debulking surgery is the first choice of management for most patients with ovarian cancer [5] , but most ovarian cancers recur after surgery and are intractably drug resistant [6] . Therefore, although some advances in cytoreductive surgery and case-effective chemotherapy have been made in the last decade, the prognosis for ovarian cancer, especially for epithelial ovarian cancer still is limited.
In most tertiary medical centers, magnetic resonance (MR) imaging is generally performed for imaging assessment of complex ovarian masses [7, 8] that are indeterminate on either palpation or ultrasonography because of MR's superb soft-tissue resolution and lack of radiation. The MR diagnostic criteria for ovarian malignancies are based on morphology: thick septum, vegetations, ascites, lymphadenopathy, and vividly enhancing solid component, which are features well described in numerous reports [8, 9] . However, identification of the tumor tissues at an early stage with available imaging modalities still possesses a great challenge for both radiologists and clinicians.
Recent advances in nanoscience and nanotechnology have enabled the development of various contrast agents for MR imaging applications, such as Gd (III)-or Mn (II)-based T 1 MR contrast agents [10, 11] and magnetic iron oxide nanoparticle (Fe 3 O 4 NPs)-based T 2 MR contrast agents [12] [13] [14] . The Fe 3 O 4 NPs are the most commonly used magnetic materials for various biomedical applications [15] [16] [17] [18] . But, few reports on the application of Fe 3 O 4 NPs for the diagnosis of ovarian cancer have been published.
Folic acid (FA) receptors as single-chain glycoproteins with high specific affinity for FA are highly overexpressed on various malignant tumors, including human ovarian cancer [19] . The over-expression of FA receptors on malignant tumor tissues can be exploited as a specific targeting ligand since most healthy tissues have little FA receptors expression [20] . This targeting strategy has the potential for diagnostic and therapeutic application in a wide variety of cancers [21, 22] .
In this research, we used FA-targeted Fe 3 O 4 NPs as T 2 -negative contrast agents for in vivo MR imaging of ovarian cancer in an intraperitoneal xenograft tumor model. To the best of our knowledge, this is the first reported application of FA-targeted Fe 3 O 4 NPs in MR imaging diagnosis of ovarian cancer.
Methods

Synthesis and characterization techniques
FA-targeted Fe 3 O 4 NPs were synthesized and characterized according to our previous work [23] . Non-targeted Fe 3 O 4 NPs were synthesized by the same methods, except for the use of mPEG-COOH in the PEGylation step instead of FA-PEG-COOH.
Branched polyethyleneimine (PEI, Mw = 25,000)-coated Fe 3 O 4 NPs (Fe 3 O 4 @PEI NPs) were synthesized via a reduction route. FeCl 3 · 6H 2 O (1.3 g) was dissolved in 20 mL water, and placed into a 250 mL three-necked flask. Under vigorous stirring, the solution was bubbled with nitrogen atmosphere for 15 min, then 10 mL freshly prepared sodium sulfite solution (0.2 g) was added slowly into the flask. 30 min later, 5 mL PEI (0.5 g) and 2 mL ammonia (25 %) was added into the flask successively. The reaction mixture was vigorously stirred for 30 min at 60~70 o C, and then at room temperature for another 1.5 h. The product (Fe 3 O 4 @PEI NPs) was magnetically collected and washed 3 times with water. Finally, the sample was centrifuged (8000 rpm, 10 min) to remove the aggregation and larger particles.
An The Leeman Prodigy inductively coupled plasma-optical emission spectroscopy (ICP-OES, Hudson, NH, USA) also was used to quantify the cellular uptake of the Fe 3 O 4 NPs by Skov-3 cells. The Skov-3 cells were seeded into 12-well plates with a density of 1 × 10 6 cells/well. After overnight incubation to bring the cells to confluence, the medium was discarded carefully, and 1 mL fresh medium containing PBS buffer (control), FA-targeted Fe 3 O 4 NPs or nontargeted Fe 3 O 4 NPs at Fe concentrations of 0.2 and 0.4 mM was added. The cells were further incubated at 37°C and 5 % CO 2 for 4 h. The medium was then removed. The cells were washed with PBS buffer four times, trypsinsized, collected, and suspended in 1 mL PBS buffer. The cell numbers in each sample were estimated with a hemocytometer. For the cellular uptake assay, the cells were centrifuged (1000 rpm, 5 min), collected, and lysed with an aqua regia solution (0.5 mL) for 12 h. The Fe content was determined by ICP-OES after the samples were diluted 2 times with PBS. 
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Statistical analysis
Quantitative data were expressed as mean ± standard deviation (SD). Means were compared by use of unpaired two-sided Student's t-test. The data are indicated with (*) for p < 0.05, (**) for p < 0.01 and (***) for p < 0.001.
Results
Synthesis and characterization techniques
The morphology of the FA-targeted Fe 3 O 4 NPs and nontargeted Fe 3 O 4 NPs was characterized by TEM (Fig. 1) . It can be seen that the NPs with a spherical or quasispherical shape have a quite uniform size distribution and a polymer shell on their outer surface. The mean size was measured to be 8.7 ± 1.9 nm for non-targeted Fe 3 O 4 NPs (Fig. 1a ) and 9.2 ± 1.7 nm for FA-targeted Fe 3 O 4 NPs (Fig. 1b) It is important to assess the potential cytotoxicity of (Fig. 5) (Fig. 7) . In the MR images, we can see the contrast enhancement was highest at 2 h post injection. After that, the tumor signal recovered because of further metabolism. Quantitative analysis of the T 2 signal intensity of solid tumors at various time points revealed that the lowest signal intensity occurred at 2 h after injection with both the FAtargeted Fe 3 O 4 NPs and non-target Fe 3 O 4 NPs (Fig. 8) 
Discussion
In this study, we report our preliminary experience in imaging human ovarian cancer in the xenograft tumor model by using FA-targeted Fe 3 O 4 NPs as contrast agents. Owing to the good contrast enhancement and low cytotoxicity, the FA-targeted Fe 3 O 4 NPs can detect the ovarian cancer tissues planted in the abdominal cavity of nude mice at in vivo levels. Our results indicated that FA-targeted Fe 3 O 4 NPs hold promise for being effective magnetic molecular probes for detecting tumor tissues in gynecologic cancer.
Ovarian cancer is the most malignant gynecological tumor and therefore deserves extensive basic and clinical research in the quest for early diagnostic tests and effective treatments [24] [25] [26] [27] . Fe 3 O 4 NPs are low-toxic and eventually biodegrade to form blood hemoglobin [14] , and they have been used for liver imaging since the 1900s [28] . With recent advances in nanotechnology and nanoscience [29] [30] [31] [32] , various polymers have been coated onto the surface of Fe 3 O 4 NPs to improve their stability and decrease their uptake by the reticuloendothelial system [16, 33, 34] . Numerous studies on application of NPs in biomedical imaging have been reported in recent decades [35] [36] [37] [38] [39] [40] , but few have examined application of the particles in ovarian cancer.
In our previous work, we demonstrated that FA-targeted Fe 3 O 4 NPs have good water-dispersibility, colloidal stability and fairly high relaxivity [23] . In addition, the particles have excellent hemocompatibility and cytocompatibility in the studied range of concentrations. We found that FAtargeted Fe 3 O 4 NPs had excellent binding specificity to a human cervical cancer cell line (HeLa cells) overexpressing FA receptors via an active FA targeting pathway. In the present study, we found excellent lesion targeting ability of the FA-targeted Fe 3 O 4 NPs to ovarian cancer in the T 2 -weighted MR imaging, which may be attributed to the following aspects: First, although the mean size of the FA-targeted Fe 3 O 4 NPs was small (9.2 ± 1.7 nm), the particles had a very high r 2 relaxivity coefficients (475.92 mM
), which is much higher than those of other reported Fe 3 O 4 NPs [33, 40] . This feature made the particles more sensitive to magnetic susceptibility effects. Second, the presence of FA on the surface of the Fe 3 O 4 NPs increased their ability to target tumor tissues. Third, the passive enhanced permeability and retention effect into solid tumors may also facilitate the specific MR imaging of tumors [36] .
Human ovarian cancers are located deep in the pelvic space [41] . An ideal humanized xenograft mouse model of ovarian cancer would simulate the true microenvironment for tumor angiogenesis [24, [42] [43] [44] . Thus, in the present study, we implanted the tumor cells in the abdomen rather than in subcutaneous sites, believing that the intraperitoneal location would reflect the hemodynamic condition of ovarian cancer in humans-at least more accurately than would a subcutaneous site, as has been often used [10] [11] [12] 25] . Our results corroborated this point: both targeted and non-targeted particles were evident by T 2 -weithted MR imaging at 2 h after injection in abdominal tumors compared with 1 h in subcutaneous tumors [23] , perhaps because more time was needed for Fe 3 O 4 NPs to reach the deep abdominal tumors in sufficient concentration to be evident on T 2 -enhanced imaging. We must confess that the T 2 signal intensity in MR images also achieve the lowest point at 2 h post injection of non-targeted Fe 3 O 4 NPs, which may be due to the enhanced permeability and retention (EPR) effect (passive uptake) as well documented in solid tumors [14, 36, 37] . However, both in vitro and in vivo imaging results (as shown in Figs. 5 and. 7) proved FA-targeted Further, we also found that, after injection of Fe 3 O 4 NPs in the nude mice, the tumor T 2 signal intensity had reverted to pre-injection intensity after 4 h, a little earlier than that we had found previously in subcutaneous tumors [23] . We also acknowledge that the injection of suspensions of tumor cells into the mice is different from the formation of tumors in the natural environment.
Other methods for imaging detection of ovarian cancers have been described. Hensley, et al [45] described a dual MR-fluorescence molecular tomography approach, with commercially available fluorescent molecular imaging probes for the detection and quantification of tumorassociated metabolites in ovarian carcinomas in a transgenic mouse model of epithelial ovarian cancer. The authors concluded that the combination of in vivo molecular and MR imaging can effectively detect orthotopic ovarian tumors and their response to therapy [25] . In another study, Satpathy, et al [24] reported that in an orthotopic human ovarian tumor xenograft model, HER-2-targeted magnetic NPs labeled with a near infrared dye (NIR-830) were specifically delivered into primary and disseminated ovarian tumors, enabling optical and MR imaging of tumors as small as 1 mm in the peritoneal cavity. The authors designed the non-conjugated magnetic NPs with 14 ± 3.4 nm diameter and targeted-conjugated magnetic NPs with 22.9 ± 4.8 nm diameter, respectively [24] . However, they did not report the exact MR acquisition time point, which we believe is crucial for tumor imaging, especially for magnetic NPs.
Our study also has some limitations. First, by 2 weeks after injection of ovarian cancer cells into the peritoneal cavity, the tumors often had become large (average diameter about 5 mm) with isointensity signals on T 2 -weighted MR imaging making them easily detectable and distinct from surrounding tissues, which had mostly hyperintensity signals. However, tumors at an earlier stage or smaller might not be detected because of overlapping neighboring organs (such as gut, kidney, or bladder) and background tissues. Perhaps the specificity and sensitivity could be improved by the use of bimodal magnetic nanoprobes with fluorescent materials incorporated into Fe 3 O 4 NPs. Second, since FA receptors are overexpressed in most malignant tumors, the FA targeting ligand we used may not be specific for detecting ovarian cancer. Further studies should be conducted to image ovarian cancer with targeting motifs that may be more specific.
Conclusion
In summary, this study demonstrated that the prepared FA-targeted Fe 3 O 4 NPs can bound specifically in vitro to the FA receptors overexpressed human serous ovarian cells without inducing cytotoxicity. Used as T 2 -negative contrast agents in MR imaging, the particles also localized to intraperitoneal human ovarian cancer tissues in a xenograft tumor model. Importantly, the tumor can be detected more obviously after the mice were injected with FA-targeted Fe 3 O 4 NPs than non-targeted Fe 3 O 4 NPs. Thus, FA-targeted Fe 3 O 4 NPs hold promise that they may be multifunctional nanoprobes for the diagnosis and treatment of ovarian cancer.
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